门诊全膝关节置换术后补充口服甲泼尼龙包的结局:匹配队列研究
该回顾性匹配队列研究纳入366例在门诊专科医院因终末期骨关节炎行初次全膝关节置换术的患者,按出院时是否接受口服甲泼尼龙包以1:2倾向性评分匹配(122例用药组 vs 244例对照组),比较术后90天结局及额外阿片类药物消耗。结果显示口服甲泼尼龙未显著减少阿片类药物消耗,但与更高的当日出院率相关,且与更多手法松解相关;并发症、再入院及假体周围感染翻修无显著差异。
要点
- 口服甲泼尼龙未减少术后0-14天及15-30天阿片类药物消耗。
- 用药组当日出院率更高(54.9% vs 31.1%,P<0.001)。
- 用药组术后手法松解率更高(5.7% vs 1.2%,P=0.018)。
核心结论
- 在这项回顾性研究中,门诊初次全膝关节置换术后口服甲泼尼龙作为多模式方案的一部分似乎是安全的。
- 皮质类固醇使用未减少阿片类药物消耗,且与更高的手法松解率相关。
- 作者认为样本量小、数据脆弱,不应过度解读,需更大规模前瞻性研究澄清。
研究设计与样本
- 回顾性研究,纳入366例在门诊专科医院因终末期骨关节炎行初次全膝关节置换术的连续患者。
- 根据出院时是否接受口服甲泼尼龙包,按特定患者合并症以1:2比例进行倾向性评分匹配(122例用药组 vs 244例对照组)。
- 用药组2型糖尿病患者16例(13.1%),对照组45例(18.4%),P=0.254。
- 暴露分配基于时间,特定日期后所有患者均被处方甲泼尼龙包。
- 比较术后90天结局及以吗啡毫克当量(MMEs)衡量的额外阿片类药物消耗。
主要发现
- 术后并发症发生率用药组4.9% vs 对照组1.6%,P=0.090。
- 再入院率用药组2.5% vs 对照组3.7%,P=0.758。
- 因假体周围感染翻修率用药组0% vs 对照组1.2%,P=0.306。
- 用药组当日出院率54.9% vs 对照组31.1%,P<0.001。
- 用药组后续手法松解率5.7% vs 对照组1.2%,P=0.018。
临床怎么用
- 门诊全膝关节置换术后口服甲泼尼龙可作为多模式方案的一部分,但需注意其未减少阿片消耗且手法松解率更高。
- 处方甲泼尼龙包可能提高当日出院率,但应权衡手法松解风险。
- 鉴于样本量小和数据脆弱性,临床决策应结合更大规模前瞻性研究结果。
局限性
- 回顾性研究设计。
- 总体样本量小,作者承认数据脆弱。
- 暴露分配基于时间,可能存在时间偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The growing expansion of outpatient total knee arthroplasty (TKA) and emphasis on multimodal pain control to reduce opioid consumption are essential in optimizing perioperative care. This study aimed to assess postoperative outcomes when prescribing a supplemental oral methylprednisolone after primary TKA. METHODS: This retrospective study included 366 consecutive patients who underwent primary TKA for end-stage osteoarthritis at an outpatient specialty hospital. Patients were propensity score matched according to specific patient comorbidities at a 1:2 ratio (122:244 case:control) based on whether they received oral methylprednisolone at discharge. The methylprednisolone group included 16 (13.1%) patients who had type II diabetes versus 45 (18.4%) in the control group (P = 0.254). Exposure assignment was time-based, with all patients prescribed the methylprednisolone pack following a specific date. Postoperative 90-day outcomes and additional opioid consumption measured in morphine milligram equivalents (MMEs) were compared. RESULTS: Postoperative complications (4.9 versus 1.6%, P = 0.090), readmissions (2.5 versus 3.7%, P = 0.758), and revisions for periprosthetic joint infection (0 versus 1.2%, P = 0.306) did not differ significantly between the oral methylprednisolone and control groups. Patients who received oral methylprednisolone were discharged the same day more often (54.9 versus 31.1%, P < 0.001), but underwent more subsequent manipulations under anesthesia (5.7 versus 1.2%, P = 0.018). The mean MME consumption was not reduced at the 0 to 14 (383 versus 417 MMEs; P = 0.535) or 15 to 30 (422 versus 445 MMEs; P = 0.954) postoperative day intervals. CONCLUSIONS: Oral methylprednisolone appeared safe in this retrospective study as part of a multimodal regimen following outpatient primary TKA. Although corticosteroid use did not reduce opioid consumption and was associated with higher manipulation rates, larger prospective studies are warranted to clarify these findings. Considering the small overall sample, we recognize that the data are fragile and should not be overinterpreted.
引用
- Lam AD, Foreman SR, Davidson SJ, et al. Outcomes Following Supplementary Oral Methylprednisolone Pack After Outpatient Total Knee Arthroplasty: A Matched Cohort Study. J Arthroplasty. 2026. PMID: 41963222. doi:10.1016/j.arth.2026.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。